HA
AZN icon

Hamel Associates’s AstraZeneca AZN Stock Holding History

Hamel Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$845K Sell
4,456
-155
-3% -$29.2K 0.23% 58
2026
Q1 		$909K Buy
4,611
+684
+17% +$132K 0.26% 55
2025
Q4 		$722K Buy
+3,927
New +$689K 0.22% 58

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $2.92B AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Hamel Associates's AZN Position: Q2 2026 in Review

Hamel Associates reduced its AstraZeneca (AZN) stake by 3.4% in Q2 2026, selling an estimated $29.2K and leaving 4,456 shares worth $845K. The position accounts for 0.23% of the portfolio, ranked #58.

Hamel Associates first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $909K in Q1 2026. 655 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Hamel Associates held 4,456 shares of AstraZeneca worth $845K as of Q2 2026.
  • Hamel Associates sold 155 AstraZeneca shares in Q2 2026, an estimated $29.2K.
  • AstraZeneca made up 0.23% of Hamel Associates's portfolio in Q2 2026, its #58 holding.
  • Hamel Associates first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Hamel Associates's AstraZeneca position peaked at $909K in Q1 2026.
  • 655 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Hamel Associates's 13F filing for Q2 2026, filed 27 Jul 2026.